Skip to main content

Table 1 Mocetinostat improved left ventricular function in CHF

From: HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation

  Heart rate (bpm) Maximum pressure (mmHg) End-diastolic pressure (mmHg) Ejection fraction (%) Cardiac output (μL/min) LV dP/dt max (mmHg/s)
CHF + MOCE 243.7 ± 21.1 110.5 ± 12.1 9.4 ± 3.4a 42.1 ± 14.3 23,234 ± 12,996 5,573 ± 689a
CHF 235.8 ± 16.1 102.7 ± 12.3b 28.7 ± 6.2b 33.6 ± 8.1b 19,001 ± 6,082b 3,921 ± 816b
SHAM 261.1 ± 39.4 122.5 ± 13.8 7.2 ± 2.3 63.0 ± 10.2 40,162 ± 16,010 6,928 ± 1,090
  1. Hemodynamic parameters were measured in sham, CHF and CHF treated with Mocetinostat. Sham (n = 8), CHF (n = 10), CHF + MOCE (n = 8). Data are presented as mean ± SD.
  2. aCHF + MOCE vs CHF, P <0.01.
  3. bCHF vs. SHAM, P <0.01.
  4. CHF, congestive heart failure; LV dP/dtmax, peak rate of left ventricular pressure rise; MOCE, Mocetinostat.